|
Licenses Acquired - Additional Information (Detail) (USD $)
|
3 Months Ended | ||||
|---|---|---|---|---|---|
|
Mar. 31, 2015
|
Mar. 31, 2014
|
||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
| Payments to Acquire Intangible Assets | $ 1,250,000us-gaap_PaymentsToAcquireIntangibleAssets | $ 0us-gaap_PaymentsToAcquireIntangibleAssets | |||
| Research And Development In Process | 7,439,000us-gaap_ResearchAndDevelopmentInProcess | 0us-gaap_ResearchAndDevelopmentInProcess | |||
| Mustang Bio, Inc [Member] | |||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
| Payments to Acquire Intangible Assets |
2,000,000us-gaap_PaymentsToAcquireIntangibleAssets / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = fbio_MustangBioIncMember |
||||
| Stock Issued, Value, Issued for Noncash Consideration |
260,000us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = fbio_MustangBioIncMember |
||||
| Coronado SO Co, Inc [Member] | |||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
| Payments to Acquire Intangible Assets |
929,000us-gaap_PaymentsToAcquireIntangibleAssets / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = fbio_CoronadoSoCoIncMember |
||||
| Stock Issued, Value, Issued for Noncash Consideration |
250,000us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = fbio_CoronadoSoCoIncMember |
||||
| Research And Development In Process |
$ 1,179,000us-gaap_ResearchAndDevelopmentInProcess / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = fbio_CoronadoSoCoIncMember |
[1] | |||
|
|||||
| X | ||||||||||
|
- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of shares issued for noncash consideration for development stage entities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|